Search results for " STATIN"

showing 10 items of 36 documents

The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg)

2021

Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effecti…

Microbiology (medical)medicine.medical_specialtyMultivariate analysisHelicobacter pylori statins treatmentRM1-950BiochemistryMicrobiologyArticlestatinsRescue therapyInternal medicineIn real lifeMedicinePharmacology (medical)General Pharmacology Toxicology and Pharmaceuticsstatins ; Helicobacter pylori ; treatmentbiologyHelicobacter pyloritreatmentbusiness.industry<i>Helicobacter pylori</i>StatinStatin treatmentHelicobacter pyloribiology.organism_classificationTreatmentInfectious DiseasesTherapeutics. Pharmacologybusiness
researchProduct

STILI DI VITA E STATINE NELLA PREVENZIONE DELLE MALATTIE CARDIOVASCOLARI

2010

PREVENZIONE CARDIOVASCOLARE- STATINE - STILI DI VITA
researchProduct

Statins and angiogenesis in non-cardiovascular diseases.

2022

Statins inhibit HMG-CoA reductase by competitively inhibiting the active site of the enzyme, thus preventing cholesterol synthesis and reducing the risk of developing cardiovascular disease. Many pleiotropic effects of statins have been demonstrated that can be either related or unrelated to their cholesterol-lowering ability. Among these effects are their proangiogenic and antiangiogenic properties that could offer new therapeutic applications. In this regard, pro- and anti-angiogenic properties of statins have been shown to be dose dependent. Statins also appear to have a variety of non-cardiovascular angiogenic effects in many diseases, some examples being ocular disease, brain disease, …

PharmacologyCholesterolNeovascularization PathologicCardiovascular DiseasesNeoplasmsDrug DiscoveryHumansHydroxymethylglutaryl-CoA Reductase InhibitorsAngiogenesis Bone disease Brain disease Cancer Cardiovascular Diabetes Ocular disease Preeclampsia Statins VascularizationDrug discovery today
researchProduct

Statins and new-onset diabetes

2013

Statins are highly efficacious lipid modifying agents that reduce the risk for cardiovascular (CV) events in both primary and secondary prevention settings. However, statins affect molecular mechanisms which adversely impact on insulin sensitivity and β-cell function, thereby increasing risk for new onset diabetes mellitus (NOD). Defining the mechanisms involved is the focus of considerable current investigation. The statins reduce the risk for CV events in normoglycemic patients as well as in those with diabetes mellitus (DM) and their benefits outweigh the risk of inducing NOD. We review the clinical evidence for NOD with statin treatment, as well as the potential mechanisms involved. Our…

PharmacologySecondary preventionLIPID MODIFYING AGENTSbusiness.industrynutritional and metabolic diseasesInsulin sensitivityNodPharmacologyStatin treatmentBioinformaticsmedicine.diseaseRisk AssessmentPrimary PreventionDiabetes Mellitus Type 2New onset diabetesCardiovascular DiseasesDiabetes mellitusDrug DiscoverySecondary PreventionmedicineHumansHydroxymethylglutaryl-CoA Reductase InhibitorsRisk assessmentbusinessnew-onset diabetes mellitus statin cardiovascular events insulin sensitivity primary prevention secondary prevention
researchProduct

The Role of Nutraceuticals in Statin Intolerant Patients.

2018

Abstract Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activ…

Statinmedicine.drug_classDiseasecardiovascular risk ; dyslipidemia ; nutraceuticals ; position paper ; statin intolerance030204 cardiovascular system & hematologyBioinformaticsKlinikai orvostudományok03 medical and health sciences0302 clinical medicineNutraceuticalEzetimibeStatin intoleranceRed yeast riceMedicineHumansPosition paper030212 general & internal medicineEndothelial dysfunctionDyslipidemiasbusiness.industryClinical Studies as TopicOrvostudományokmedicine.diseaseCardiovascular risk3. Good healthDyslipidemiaDietary SupplementsArterial stiffnesslipids (amino acids peptides and proteins)nutraceuticalHydroxymethylglutaryl-CoA Reductase InhibitorNutraceuticalsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessDyslipidemiaposition papermedicine.drugstatin intoleranceHuman
researchProduct

Venous Thrombosis Associated with HMG-CoA Reductase Inhibitors

2013

Abstract Among the various hypolipidemic drugs, 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (also known as "statins") belong to a heterogeneous class of compounds, sharing an identical hypocholesterolemic effect that develops through direct inhibition of a rate-limiting step in endogenous cholesterol synthesis. Their mechanism of action entails competitive inhibition of HMG-CoA reductase. Several lines of evidence suggest that the pleiotropic effects of statins may also play a role in prevention of venous thrombosis, wherein hypercholesterolemic patients are characterized by enhanced thrombin generation, increased susceptibility to endothelial dysfunction and plate…

Statinmedicine.drug_classHMG-CoA; statins; thrombosisPharmacologyReductaseRisk AssessmentstatinsHyperlipoproteinemia Type IIHMG-CoARisk FactorsmedicineHumansPlateletEndothelial dysfunctionthrombosisHypolipidemic AgentsVenous Thrombosisbiologybusiness.industryC-reactive proteinHematologymedicine.diseaseThrombosisVenous thrombosisHMG-CoA reductasebiology.proteinHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessSeminars in Thrombosis and Hemostasis
researchProduct

Phenotypical and Functional Alteration of &gamma;&delta; T Lymphocytes in COVID-19 Patients: Reversal by Statins

2022

(1) Background: statins have been considered an attractive class of drugs in the pharmacological setting of COVID-19 due to their pleiotropic properties and their use correlates with decreased mortality in hospitalized COVID-19 patients. Furthermore, it is well known that statins, which block the mevalonate pathway, affect &gamma;&delta; T lymphocyte activation. As &gamma;&delta; T cells participate in the inflammatory process of COVID-19, we have investigated the therapeutical potential of statins as a tool to inhibit &gamma;&delta; T cell pro-inflammatory activities; (2) Methods: we harvested peripheral blood mononuclear cells (PBMCs) from COVID-19 patients with mild clinical manifestatio…

T-Lymphocyte SubsetsSARS-CoV-2 infectionLeukocytes Mononuclearmevalonate pathwaystatinHumansCOVID-19γδ T cells; COVID-19; SARS-CoV-2 infection; statin; mevalonate pathwayReceptors Antigen T-Cell gamma-deltaGeneral MedicineHydroxymethylglutaryl-CoA Reductase Inhibitorsγδ T cellsCOVID-19 Drug TreatmentCells; Volume 11; Issue 21; Pages: 3449
researchProduct

Mipomersen: a lipid-lowering agent with a novel mechanism of action

2013

“...mipomersen is a ... valuable alternative to apheresis for patients with heterozygous familial hypercholesterolemia.”

inorganic chemicalsLdl cholesterolChemistryEndocrinology Diabetes and MetabolismMipomersenLipid-lowering agentnutritional and metabolic diseasesPharmacologybehavioral disciplines and activitieshumanitiesantisense oligonucleotides LDL cholesterol lipid lowering mipomersen statinsApheresisMechanism of actionAntisense oligonucleotidesmedicineLipid loweringmedicine.symptomCardiology and Cardiovascular Medicinehealth care economics and organizationsClinical Lipidology
researchProduct

The Effects of Statin Treatment on Serum Ferritin Levels: A Systematic Review and Meta-Analysis.

2022

Background: Statins are the most widely used drugs for decreasing elevated serum LDL-cholesterol (LDL-C) and thus for the prevention of atherosclerotic cardiovascular disease (ASCVD), but they have also some pleiotropic effects, including anti-inflammatory properties. Atherosclerosis is a low-grade inflammatory disease, and elevated ferritin is considered to be one of the markers of inflammation. Since the results of studies on the effects of statins on serum ferritin levels are conflicting, this meta-analysis was performed. Methods: A literature search was performed using major electronic databases (MEDLINE/PubMed, Scopus, Embase, and ISI Web of Science) from inception up to 5 March 2022 t…

ironlipid-lowering therapyinflammationacute-phase response cardiovascular diseases inflammation iron lipid-lowering therapy statinsGeneral Medicineacute-phase responsecardiovascular diseasesstatinsJournal of clinical medicine
researchProduct

Atherosclerosis, degenerative aortic stenosis and statins

2009

Aortic stenosis is the most common valvular heart disease among adult subjects in western countries The current treatment for aortic stenosis is aortic valve replacement. The possibility of a medical treatment that can slow the progression of aortic stenosis is very fascinating and statins have been tested to reduce the progression of degenerative aortic stenosis (DAS). The rationale for statin treatment in DAS has a deep pathophysiological substrate, in fact inflammation and lipid infiltration constitute the same histopathological pattern of both aortic stenosis and atherosclerosis and these two conditions have the same risk factors. Whether retrospective studies have shown some efficacy o…

medicine.medical_specialtyClinical BiochemistryInflammationlaw.inventionCoronary artery diseaseRandomized controlled trialAortic valve replacementlawInternal medicineDrug DiscoverymedicineAnimalsHumansPharmacologyEvidence-Based Medicinebusiness.industryvalvular heart diseaseRetrospective cohort studyAortic Valve Stenosismedicine.diseaseAtherosclerosisSettore MED/11 - Malattie Dell'Apparato Cardiovascolareatherosclerosis aortic stenosis statinStenosiscardiovascular systemCardiologyMolecular Medicinemedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCalcification
researchProduct